Uploaded November 2026 | Updated November 2026, 2 days ago
(10 Nov 2026)
RESTRICTION SUMMARY:
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
1. Close of diabetes drug Ozempic in packaging line
2. Wide of diabetes drug Ozempic in packaging line
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
3. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"I've been asked why the FDA has added a warning label. And my estimation of this is that GLP-1 medications are being so widely used and increasingly used. And secondly, there's a literature that suggests that the drugs may pose a risk for a particular form of blindness, referred to as NAION (non-arteritic anterior ischemic optic neuropathy)."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
4. Various of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
5. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"So, NAION, you might think of it as a stroke of the optic nerve. It's not a stroke in the brain proper, but rather in the connection between the eye and the visual parts deeper in the brain. It's a cable that connects the eye to the visual part of the brain. So, NAION is a condition that we believe develops because of altered blood flow to the optic nerve. Once the optic nerve is injured you lose vision because that's the only connection between the eye and the rest of the brain."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
6. Shot of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
7. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"We don't know precisely what causes NAION. We know a lot about its associations, the anatomical risks that some patients have that make them more vulnerable. We generally believe that reductions in blood pressure predispose patients to the condition, but the features that actually trigger an event, which usually occurs in one eye at a time, those specific details, mechanistic details, are not well known."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
8. Various of diabetes drug Ozempic in a box
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
9. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"So a commonly asked question is also, you know, how concerned should patients be, particularly now that the FDA has issued this warning? Well, I would just take this, the warning, as a cautionary guidance that patients should bring into their consideration. So, yes, there is an association that many people believe, the FDA believed it enough that they have issued this warning. It doesn't mean you shouldn't take the medicine. In fact, the general risk of NAION is quite low, and even though GLP-1 medications may increase the risk, the risk of any person developing it is still relatively low."
ASSOCIATED PRESS
ARCHIVE: St. Petersburg, Florida – 7 November 2023
10. Tirzepatide clinical trial participant, cooks behind an injectable pen of tirzepatide
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
11. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
ASSOCIATED PRESS
ARCHIVE: Temecula, California – 30 April 2024
12. STILL: Wegovy injectable pens
ASSOCIATED PRESS
ARCHIVE: Front Royal, Virginia – 1 March 2024
13. STILL: Donna Cooper holds up a dosage of Wegovy, a drug used for weight loss, at her home
ASSOCIATED PRESS
ARCHIVE: Temecula, California – 30 April 2024
Find out more about AP Archive: aparchive.com/HowWeWork
Twitter: twitter.com/AP_Archive
Facebook: facebook.com/APArchives
Instagram: instagram.com/APNews
You can license this story through AP Archive: aparchive.com/metadata/youtube/204941bff42d49f99692eeefdf03c6b3
(10 Nov 2026)
RESTRICTION SUMMARY:
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
1. Close of diabetes drug Ozempic in packaging line
2. Wide of diabetes drug Ozempic in packaging line
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
3. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"I've been asked why the FDA has added a warning label. And my estimation of this is that GLP-1 medications are being so widely used and increasingly used. And secondly, there's a literature that suggests that the drugs may pose a risk for a particular form of blindness, referred to as NAION (non-arteritic anterior ischemic optic neuropathy)."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
4. Various of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
5. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"So, NAION, you might think of it as a stroke of the optic nerve. It's not a stroke in the brain proper, but rather in the connection between the eye and the visual parts deeper in the brain. It's a cable that connects the eye to the visual part of the brain. So, NAION is a condition that we believe develops because of altered blood flow to the optic nerve. Once the optic nerve is injured you lose vision because that's the only connection between the eye and the rest of the brain."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
6. Shot of diabetes drug Ozempic going through automated packaging line at Novo Nordisk production facility
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
7. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"We don't know precisely what causes NAION. We know a lot about its associations, the anatomical risks that some patients have that make them more vulnerable. We generally believe that reductions in blood pressure predispose patients to the condition, but the features that actually trigger an event, which usually occurs in one eye at a time, those specific details, mechanistic details, are not well known."
ASSOCIATED PRESS
ARCHIVE: Hillerod, Denmark - 26 September 2023
8. Various of diabetes drug Ozempic in a box
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
9. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
"So a commonly asked question is also, you know, how concerned should patients be, particularly now that the FDA has issued this warning? Well, I would just take this, the warning, as a cautionary guidance that patients should bring into their consideration. So, yes, there is an association that many people believe, the FDA believed it enough that they have issued this warning. It doesn't mean you shouldn't take the medicine. In fact, the general risk of NAION is quite low, and even though GLP-1 medications may increase the risk, the risk of any person developing it is still relatively low."
ASSOCIATED PRESS
ARCHIVE: St. Petersburg, Florida – 7 November 2023
10. Tirzepatide clinical trial participant, cooks behind an injectable pen of tirzepatide
ASSOCIATED PRESS
New Orleans, Louisiana – 10 November 2026
11. SOUNDBITE (English) Dr. Joseph Rizzo, Mass General Brigham:
ASSOCIATED PRESS
ARCHIVE: Temecula, California – 30 April 2024
12. STILL: Wegovy injectable pens
ASSOCIATED PRESS
ARCHIVE: Front Royal, Virginia – 1 March 2024
13. STILL: Donna Cooper holds up a dosage of Wegovy, a drug used for weight loss, at her home
ASSOCIATED PRESS
ARCHIVE: Temecula, California – 30 April 2024
Find out more about AP Archive: aparchive.com/HowWeWork
Twitter: twitter.com/AP_Archive
Facebook: facebook.com/APArchives
Instagram: instagram.com/APNews
You can license this story through AP Archive: aparchive.com/metadata/youtube/204941bff42d49f99692eeefdf03c6b3










